| Literature DB >> 34202817 |
Florian Gessler1, Ann Kristin Schmitz2, Daniel Dubinski1, Joshua D Bernstock3, Felix Lehmann4, Sae-Yeon Won1, Matthias Wittstock5, Erdem Güresir2, Alexis Hadjiathanasiou2, Julian Zimmermann6, Wolfgang Miesbach7, Thomas Freiman1, Hartmut Vatter2, Patrick Schuss2.
Abstract
Given the ongoing global SARS-CoV-2-vaccination efforts, clinical awareness needs to be raised regarding the possibility of an increased incidence of SARS-CoV-2-vaccine-related immune-mediated thrombocytopenia in patients with intracerebral hemorrhage (ICH) secondary to cerebral sinus and vein thrombosis (CVT) requiring (emergency) neurosurgical treatment in the context of vaccine-induced immune thrombotic thrombocytopenia (VITT). Only recently, an association of vaccinations and cerebral sinus and vein thrombosis has been described. In a number of cases, neurosurgical treatment is warranted for these patients and special considerations are warranted when addressing the perioperative coagulation. We, herein, describe the past management of patients with VITT and established a literature-guided algorithm for the treatment of patients when addressing the impaired coagulation in these patients. Increasing insights addressing the pathophysiology of SARS-CoV-2-vaccine-related immune-mediated thrombocytopenia guide physicians in developing an interdisciplinary algorithm taking into account the special considerations of this disease.Entities:
Keywords: Covid-19; SARS-CoV-2; cerebral sinus and vein thrombosis (CVT); decompressive craniectomy; intracerebral hemorrhage (ICH); vaccination; vaccine-induced immune thrombotic thrombocytopenia (VITT)
Year: 2021 PMID: 34202817 DOI: 10.3390/jcm10132777
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241